for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aroa Biosurgery Ltd

ARX.AX

Latest Trade

1.06AUD

Change

-0.02(-1.85%)

Volume

252,344

Today's Range

1.05

 - 

1.08

52 Week Range

0.97

 - 

1.55

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
1.08
Open
1.05
Volume
252,344
3M AVG Volume
9.88
Today's High
1.08
Today's Low
1.05
52 Week High
1.55
52 Week Low
0.97
Shares Out (MIL)
300.73
Market Cap (MIL)
362.37
Forward P/E
-32.65
Dividend (Yield %)
--

Next Event

Half Year 2022 Aroa Biosurgery Ltd Earnings Release

Latest Developments

更多

Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M

Aroa Biosurgery Says H2 FY21 Product Revenues Grew 16% To $13.8 Mln

Aroa Biosurgery Secures FDA Clearance For New Product

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aroa Biosurgery Ltd

Aroa Biosurgery Limited is a New Zealand-based soft tissue repair company. The Company is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. It designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.

Industry

Medical Equipment & Supplies

Contact Info

64 Richard Pearse Drive, Mangere

2022

New Zealand

+64.9.8693035

http://aroabio.com/

Executive Leadership

James Neil McLean

Independent Non-Executive Chairman of the Board

Brian Ward

Chief Executive Officer, Founder, Managing Director, Director

James Agnew

Chief Financial Officer, Joint Company Secretary

Simone Von Fircks

Vice President - Operations

Brad Adams

Vice President - Commercial Operations

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, NZD)

2021

0.0K

2022(E)

0.0K
EPS (NZD)

2021

-0.025

2022(E)

-0.034
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.75
Price To Book (MRQ)
5.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.74
LT Debt To Equity (MRQ)
9.77
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up